20 PARK PLAZA, BOSTON, MA
News
Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
CervoMed's Phase 2a Trial Results on Neflamapimod Accepted at ISFTD 2026
Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRRN14A
Contested Proxy Solicitation Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence